(Q47746104)

5 February 2018

title

Beta dose-rate distributions in microscopic spherical tumors for intraperitoneal radioimmunotherapy (English)

1 reference

5 February 2018

author name string

Alasdair Syme

series ordinal

1

1 reference

5 February 2018

Steve McQuarrie

series ordinal

2

1 reference

5 February 2018

B Gino Fallone

series ordinal

3

1 reference

5 February 2018

language of work or name

English

0 references

publication date

1 August 2003

1 reference

5 February 2018

International Journal of Radiation Oncology Biology Physics

published in

1 reference

5 February 2018

volume

56

1 reference

5 February 2018

issue

5

1 reference

5 February 2018

page(s)

1495-1506

1 reference

5 February 2018

Radioactivity in blood and urine following intraperitoneal instillation of chromic phosphate in patients with and without ascites

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900408-5

7 January 2021

Therapeutic efficacy of the alpha-emitter 211At bound on microspheres compared with 90Y and 32P colloids in a murine intraperitoneal tumor model

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900408-5

7 January 2021

Distribution of intraperitoneally injected microspheres labeled with the alpha-emitter astatine (211At) compared with phosphorus (32P) and yttrium (90Y) colloids in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900408-5

7 January 2021

211At radiocolloid therapy: further observations and comparison with radiocolloids of 32P, 165Dy, and 90Y

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900408-5

7 January 2021

Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900408-5

7 January 2021

In vitro and in vivo studies on the development of the alpha-emitting radionuclide bismuth 212 for intraperitoneal use against microscopic ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900408-5

7 January 2021

Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900408-5

7 January 2021

Recent advances in radionuclide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900408-5

7 January 2021

A three-step strategy for targeting drug carriers to human ovarian carcinoma cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900408-5

7 January 2021

Absorbed doses for internal radiotherapy from 22 beta-emitting radionuclides: beta dosimetry of small spheres.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900408-5

7 January 2021

A simplified approach to beta dosimetry for small spheres labelled on the surface

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900408-5

7 January 2021

Dosimetry of intraperitoneally administered radiolabeled antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900408-5

7 January 2021

Estimates of dose to intraperitoneal micrometastases from alpha and beta emitters in radioimmunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900408-5

7 January 2021

Microdosimetry and radiocurability: modelling targeted therapy with beta-emitters

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900408-5

7 January 2021

Radiation absorbed dose estimates at the cellular level for some electron-emitting radionuclides for radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900408-5

7 January 2021

Calculation of radiation doses for nonuniformly distributed β and γ radionuclides in soft tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900408-5

7 January 2021

Comparison of 131I- and 90Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900408-5

7 January 2021

Three-dimensional tumor dosimetry for radioimmunotherapy using serial autoradiography

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900408-5

7 January 2021

Beta-ray dose distributions from point sources in an infinite water medium

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900408-5

7 January 2021

Radionuclides and carrier molecules for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900408-5

7 January 2021

Dose distributions in regions containing beta sources: large spherical source regions in a homogeneous medium.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900408-5

7 January 2021

Dose distributions in regions containing beta sources: Uniform spherical source regions in homogeneous media

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900408-5

7 January 2021

Comparisons of sectioned micro-TLD dose measurements with predicted dose from 131I-labeled antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900408-5

7 January 2021

10.1016/S0360-3016(03)00408-5

Identifiers

DOI

1 reference

5 February 2018

1 reference

5 February 2018